NCT05476042 is a Phase 2, PHASE3 clinical trial of Erythropoietin prescription in Conjunctival and Scleral Avascular Lesions, sponsored by Shahid Beheshti University of Medical Sciences.

Who is sponsoring NCT05476042?

NCT05476042 is sponsored by Shahid Beheshti University of Medical Sciences.

What drugs are being tested in NCT05476042?

Interventions in NCT05476042: Prescription of placebo, Erythropoietin prescription, Erythropoietin prescription.

What condition does NCT05476042 study?

NCT05476042 studies Conjunctival and Scleral Avascular Lesions.

Is NCT05476042 still recruiting?

NCT05476042 is currently status unknown. Last updated 27 July 2022.

Last reviewed 2022-07-27 · How we verify

NCT05476042

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Erythropoietin in the Treatment of Scleral Necrosis

Status unknown Phase 2, PHASE3 Last updated 27 July 2022

What this trial tests

Phase 2, PHASE3 trial testing Prescription of placebo in Conjunctival and Scleral Avascular Lesions in 60 participants. Status unknown.

Timeline

14 August 2022

Primary endpoint
1 November 2022

1 December 2022

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	14 August 2022
Primary completion	1 November 2022
Estimated completion	1 December 2022
Sites	1 location across Iran

Drugs / interventions tested

Prescription of placebo — full drug profile →
Erythropoietin prescription — full drug profile →
Erythropoietin prescription — full drug profile →

Conditions studied

Conjunctival and Scleral Avascular Lesions — all drugs for Conjunctival and Scleral Avascular Lesions →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

Adults 10 to 70, any sex, with Conjunctival and Scleral Avascular Lesions. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with acute avascular lesions of the conjunctiva and sclera will be included in the study. Patients will undergo a complete eye examination including a slit lamp, intraocular pressure measurement, and fundoscopy with dilated pupil. At the same time, laboratory examination including measurement of fasting blood sugar (FBS) level, complete blood count (CBC) and systemic blood pressure will be performed. Patients will be randomly divided into three groups. The groups will receive sham drops (normal saline), erythropoietin 3000 units in normal saline, and erythropoietin 6000 units in normal saline every 6 hours respectively. Meanwhile, all patients will receive the usual treatments based on the cause of scleral necrosis. Eye examinations will be done daily in the first week, every other day in the second week, and then twice a week until the complete recovery of avascular lesions. In each examination, with fluorescein staining, the size of the conjunctival epithelial defect will be determined. Also, the dimensions of the avascular area of the sclera will be determined. Other examinations include measurement of visual acuity and intraocular pressure, and the patient will be evaluated in terms of iris and retinal neovascularization. The photoslit lamp will be done before starting the study and then every week. Complete healing of the lesion is defined by complete vascularization and epithelization of the ischemia site. After the complete recovery of conjunctival and scleral necrosis, the erythropoietin drop will be stopped and the examinations including blood pressure measurement, CBC, diff and FBS will be repeated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05476042 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
Last refreshed: 27 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05476042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing